Alza Delivery Technologies Reduce Drug Enhancement Costs To $80 Mil.
Executive Summary
Alza drug delivery technologies reduce the cost of developing an enhanced version of an already-marketed drug to $70 mil.-$80 mil., Alza Chairman Sam Saks, MD, said during Johnson & Johnson's business review Sept. 23
You may also be interested in...
Lilly cashes out on dapoxetine
PPD will acquire patents to the premature ejaculation product dapoxetine from Lilly for $65 mil. Lilly will also receive 5% royalties on annual sales greater than $800 mil. The renegotiation of the development deal allows PPD to receive full royalties and milestones from Johnson & Johnson, where the product is in Phase III trials. Alza licensed dapoxetine from PPD prior to its merger with J&J (1"The Pink Sheet" Sept. 30, 2002, p. 29)...
Lilly cashes out on dapoxetine
PPD will acquire patents to the premature ejaculation product dapoxetine from Lilly for $65 mil. Lilly will also receive 5% royalties on annual sales greater than $800 mil. The renegotiation of the development deal allows PPD to receive full royalties and milestones from Johnson & Johnson, where the product is in Phase III trials. Alza licensed dapoxetine from PPD prior to its merger with J&J (1"The Pink Sheet" Sept. 30, 2002, p. 29)...
Tufts R&D Cost Estimate Puts Cash Outlay At $403 Mil. Per NCE
The cash outlay required to complete development of a new chemical entity has increased to an average of more than $400 mil., the Tufts Center for the Study of Drug Development says
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: